NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NeuroOne Appoints Jason Mills to Board of Directors
TL;DR
NeuroOne appoints Jason Mills to its Board, gaining strategic med-tech expertise and industry relationships to advance clinical goals and create shareholder value.
Jason Mills brings over two decades of med-tech investment analysis and executive strategy experience from Penumbra to NeuroOne's Board, effective December 18, 2025.
This appointment strengthens NeuroOne's mission to transform neurological disorder treatments, potentially improving patient outcomes for conditions like epilepsy and Parkinson's disease.
A former top-ranked Wall Street medical devices analyst joins NeuroOne's Board, bringing Yale economics and sports administration credentials to neurological innovation.
Found this article helpful?
Share it with your network and spread the knowledge!
NeuroOne Medical Technologies Corporation has appointed Jason Mills to its Board of Directors, effective December 18, 2025.
Jason Mills is Executive Vice President of Strategy at Penumbra, Inc., and previously served as a med-tech investment analyst for over two decades, including as Managing Director at Canaccord Genuity. He holds a BA in Economics from Yale University and a Masters in Sports Administration from Ohio University.
His appointment brings strategic experience, industry relationships, firsthand knowledge of the med-tech industry, and investment and capital markets expertise that will help NeuroOne progress on its clinical and corporate goals.
He will serve on the Compensation and Nominating & Corporate Governance Committees, and help expand NeuroOne's reach in transforming neurological disorder diagnosis and treatment.
NeuroOne develops and commercializes minimally invasive, hi-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for neurological disorders like epilepsy, Parkinson's disease, and chronic pain.
CEO Dave Rosa stated that Jason Mills brings unparalleled and invaluable experience and insights in med-tech, and his expertise will be a critical resource for the company's progress.
Chairman Paul Buckman noted that Jason Mills will help expand NeuroOne's reach as a company transforming neurological disorder treatment, positioning it to create additional value for shareholders.
For more information, visit nmtc1.com or contact IR at NMTC@mzgroup.us.
Curated from NewMediaWire
